ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
1,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
1,4,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
2,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
3,1,Headache,Headaches NEC,Headaches,Nerv,N
4,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
4,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
4,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
5,1,Headache,Headaches NEC,Headaches,Nerv,N
6,1,Headache,Headaches NEC,Headaches,Nerv,N
6,2,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
7,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
7,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
7,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
8,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
8,2,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
9,1,Headache,Headaches NEC,Headaches,Nerv,N
10,1,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
11,1,Drug clearance decreased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
12,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
12,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
12,3,Mucocutaneous candidiasis,Candida infections,Fungal infectious disorders,Infec,N
12,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
12,5,Pulmonary infarction,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
12,6,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
13,1,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
13,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
14,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
15,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
15,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
16,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
16,2,Product delivery mechanism issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
17,1,Sensitive skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
18,1,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
19,1,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
20,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
20,2,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
21,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
21,2,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
22,1,Cyst,Mass conditions NEC,Tissue disorders NEC,Genrl,N
23,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
24,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
25,1,Conjunctivitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
25,2,Hordeolum,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
25,3,Seasonal allergy,Atopic disorders,Allergic conditions,Immun,N
26,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
27,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
28,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
29,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
29,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
30,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
31,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
32,1,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
33,1,Eye inflammation,"Ocular infections, inflammations and associated manifestations","Ocular infections, irritations and inflammations",Eye,N
33,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
34,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
35,1,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
36,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
37,1,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
38,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
39,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
39,2,Keratitis,"Corneal infections, oedemas and inflammations","Ocular infections, irritations and inflammations",Eye,N
39,3,Ocular discomfort,Ocular disorders NEC,Eye disorders NEC,Eye,N
39,4,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
40,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
40,2,Keratitis,"Corneal infections, oedemas and inflammations","Ocular infections, irritations and inflammations",Eye,N
40,3,Ocular discomfort,Ocular disorders NEC,Eye disorders NEC,Eye,N
40,4,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
41,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
41,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
41,3,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
41,4,Myalgia,Muscle pains,Muscle disorders,Musc,N
41,5,Oral viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
42,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
42,2,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
43,1,Product availability issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
43,2,Product distribution issue,Product distribution and storage issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
43,3,Therapy interrupted,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
44,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
45,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
46,1,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
46,2,Headache,Headaches NEC,Headaches,Nerv,N
46,3,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
46,4,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
46,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
46,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
46,7,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
47,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
48,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
49,1,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
50,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
51,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
51,2,Impetigo,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
52,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
52,2,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
53,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
53,2,Oral mucosal discolouration,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
53,3,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
54,1,Skin plaque,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
55,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
56,1,Streptococcal infection,Streptococcal infections,Bacterial infectious disorders,Infec,N
57,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
57,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
57,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
57,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
57,5,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
58,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
59,1,Ear pain,Ear disorders NEC,Aural disorders NEC,Ear,N
59,2,Facial pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
59,3,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
60,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
61,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
62,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
63,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
64,1,Ear infection,Ear infections,Infections - pathogen unspecified,Infec,N
65,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
66,1,Multiple-drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
66,2,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
66,3,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
67,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
67,2,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
67,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
68,1,Headache,Headaches NEC,Headaches,Nerv,N
69,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
69,2,Gingivitis ulcerative,"Gingival disorders, signs and symptoms NEC",Dental and gingival conditions,Gastr,N
69,3,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
70,1,Folliculitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
71,1,Oesophageal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
72,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
72,2,Vulvovaginal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
73,1,Hidradenitis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
74,1,Graft infection,Infections NEC,Infections - pathogen unspecified,Infec,N
75,1,Hordeolum,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
76,1,Hordeolum,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
77,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
78,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
79,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
79,2,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
80,1,Acne,Acnes,Skin appendage conditions,Skin,N
81,1,Headache,Headaches NEC,Headaches,Nerv,N
82,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
83,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
84,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
84,2,Toothache,Dental pain and sensation disorders,Dental and gingival conditions,Gastr,N
85,1,Candida infection,Candida infections,Fungal infectious disorders,Infec,N
86,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
86,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
86,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
86,4,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
86,5,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
86,6,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
87,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
88,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
88,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
88,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
89,1,Vulvovaginal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
90,1,Blepharitis,"Lid, lash and lacrimal infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
90,2,Candida infection,Candida infections,Fungal infectious disorders,Infec,N
91,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
92,1,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
92,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
93,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
94,1,Vulvovaginal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
95,1,Hidradenitis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
96,1,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
96,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
96,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
97,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
97,2,Psoriasis area severity index increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
98,1,Myopathy,Myopathies,Muscle disorders,Musc,N
99,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
100,1,Lichen planus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
101,1,Myopathy,Myopathies,Muscle disorders,Musc,N
102,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
102,2,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
102,3,Hepatic steatosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
102,4,Lipids increased,Lipoprotein and lipid tests NEC,Lipid analyses,Inv,N
102,5,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
103,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
103,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
104,1,Ageusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
104,2,Burning mouth syndrome,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
104,3,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
104,4,Irritable bowel syndrome,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
104,5,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
104,6,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
105,1,Inflammatory bowel disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
106,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
107,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
107,2,Vulvovaginal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
108,1,Administration site pain,Administration site reactions NEC,Administration site reactions,Genrl,N
108,2,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
109,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
109,2,Headache,Headaches NEC,Headaches,Nerv,N
109,3,Respiratory tract infection,Infections NEC,Infections - pathogen unspecified,Infec,N
109,4,Vulvovaginal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
110,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
111,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
111,2,Hypoaesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
111,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
112,1,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
112,2,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
112,3,Oral mucosal exfoliation,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
113,1,Vulvovaginal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
114,1,Dyshidrotic eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
115,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
115,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
115,3,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
115,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
116,1,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
117,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
118,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
119,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
119,2,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
120,1,Vulvovaginal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
121,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
121,2,Seborrhoeic dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
122,1,Vulvovaginal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
123,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
124,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
124,2,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
125,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
126,1,Paradoxical drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
126,2,Seborrhoeic dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
127,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
127,2,Headache,Headaches NEC,Headaches,Nerv,N
127,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
127,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
128,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
129,1,Seborrhoeic dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
130,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
130,2,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
130,3,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
131,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
132,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
132,2,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
132,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
132,4,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
133,1,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
133,2,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
133,3,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
134,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
134,2,Paradoxical psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
135,1,Axial spondyloarthritis,Spondyloarthropathies,Joint disorders,Musc,N
135,2,Bursitis,Bursal disorders,Synovial and bursal disorders,Musc,N
135,3,Fungal infection,Fungal infections NEC,Fungal infectious disorders,Infec,N
135,4,Hyperlipidaemia,Hyperlipidaemias NEC,Lipid metabolism disorders,Metab,N
136,1,Ulcerative keratitis,"Corneal infections, oedemas and inflammations","Ocular infections, irritations and inflammations",Eye,N
137,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
137,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
137,3,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
137,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
137,5,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
138,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
139,1,Psoriasis,Psoriatic conditions,Epidermal and dermal conditions,Skin,N
140,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
140,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
140,3,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
140,4,Mass,Mass conditions NEC,Tissue disorders NEC,Genrl,N
140,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
140,6,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
141,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
142,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
143,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
144,1,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
145,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
146,1,Coeliac disease,Malabsorption syndromes,Malabsorption conditions,Gastr,N
147,1,Crohn's disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
148,1,Ear swelling,Ear disorders NEC,Aural disorders NEC,Ear,N
148,2,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
149,1,Candida infection,Candida infections,Fungal infectious disorders,Infec,N
150,1,Limb injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
151,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
152,1,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
153,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
153,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
153,3,Oral mucosal blistering,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
154,1,Candida infection,Candida infections,Fungal infectious disorders,Infec,N
